

0002

APPENDIX 1 MSC 94.1 - 18 MAY 94

Initial	Meeting	Item	Action	Progress	Target Date
JDC	11/93	3.1.1	to write to UKTSSA requesting them to continue providing tissue typing plates.	Complete	
AK	11/93	3.1.2	to establish whether Scottish Office contribute funds to UKTSSA.		
JDC	11/93	3.1.3	If UKTSSA pulls out - invite SNBTS Centres to tender for provision TT plates.	No longer relevant	
ALL	11/93	3.1.4	Consider creation of steering group.	No longer relevant	
GG	11/93	3.2. li	Send copies of bone donor and blood donor A-Z guidelines to Dr Gunson.		
JDC	11/93	3.2.3i	Request a copy of the UKTSSA/NIBSC draft 'Promoting the safety of transplantation of human tissues and organs'.	Done, sent to 22.12.93	(SJU, SL)
SJU	11/93	3.2.3ii	Include in the SNBTS response to the above document a compendium of relevant SNBTS info eg bone donor A-Z, labelling etc.		
JDC	11/93	3.2.3iii	Write to Dr Wagstaff requesting that tissue banking be included in Red Guide.	OK. Watching meantime	brief
MB/JDC	11/93	3.2.4	Invite Dr Lumley to prepare a discussion paper on PCR testing of bone/tissue donors.	Onto discussion 2, this agenda)	list (appendix
DBLMcC	11/93	4.1. li	Obtain a 3 month progress report from Dr McMenemin.	<i>M/Barc</i>	
DBLMcC	11/93	4.1. lii	Confirm the nature of the contract between CRAG and CDSU, confirm continuity of funding, communicate → JDC/AK.		
GG	11/93	4.1.2ii	Explore potential for a single UK A-Z	NBA have issued their own version. (UK) A-Z has been approved	issued their A unified been in principle
JDC	11/93	4.1.2iii	Consult with Dr Gunson to establish a UK position on CJD.		
GG	11/93	4.1.3	include "sexual partners of anti-HCV positive individuals" on next MAC/SAC meetings.		

Initial	Meeting	Item	Action	Progress	Target Date
CVP	11/93	4.2.7	Provide an update on IVIgG.	Onto discussion (appendix 2,	list this agenda)
DBLMcC	11/93	4.3.1	Report for MSC re problems in antenatal administration of anti-D.	Onto discussion (appendix 2,	list this agenda)
DBLMcC	11/93	4.3.2	Implement an audit of platelet therapy.	Onto discussion (appendix 2,	list this agenda)
DBLMcC	11/93	4.3.3	Investigate and report on the provision of Rh negative platelets.	Onto discussion (appendix 2,	list this agenda)
GG	11/93	4.3.4	Report for MSC on audit of donor deferrals in NE & SE RTCs.	Onto discussion (appendix 2,	list this agenda)
DBLMcC	11/93	4.3.5	Update re 'Patient Perceptions and Experiences of Blood Transfusion'.		
DBLMcC RTDs	11/93	4.3.6	Send draft CRAG report to RTDs for comments. Comment on draft		
DBLMcC	11/93	4.3.8	Prepare/present discussion document on MAC focus.	Onto discussion (appendix 2,	list this agenda)
MB	11/93	4.4.1iv	Revise "470mL" document	Complete	
MB	11/93	4.4.1v	Issue "470mL" document to RTDs	Complete	
JDC	11/93	4.4.1vi	Ask Dr Gillon to make available the SE data on faints.	Done, preliminary	data available
RTDs	11/93		Encourage the generation of local data on incidence of donor faints re 470mL donation.		
MB	11/93	4.4.2	Provide further information on the SBA.	Complete	
MB	11/93	4.5.1	Investigate NERTC red cell production.	meeting arranged	
MB	11/93	4.5.2	Advance the SNBTS reagent price list for charging private hospitals.	in progress	
EF	11/93	4.6.1	Prepare and provide a summary of the key features of the appendices to the MRU annual report.		
JDC	11/93	4.6.3	Advise the General Manager that the MSC felt there was a need for flexibility in the SNBTS approach to donor privacy.	Done	
JDC	11/93	4.6.4	Ensure that "lookback-HCV" receives further discussion.	Being discussed Onto discussion (appendix 2,	by ACTTI list this agenda)
DBLMcC	11/93	4.6.4	Circulate lookback information produced by SE RTC.		

Initial	Meeting	Item	Action	Progress	Target Date
JDC	11/93	4.6.6i	Advise manufacturers of new SNBTS 'rules of engagement'.	Consideration is to issuing SOP	being given 331.0001
COR/EF/ JDC	11/93	4.6.7	Complete the evaluation of 3rd Generation Abbott anti-HCV kits.	Complete. approved by IDC on 12/1/94 homologate.	MSC to
RM	11/93	4.6.8	Produce an annual report on the activities of the COR.		
SJU	11/93	4.7.1	brief the Committee on developments re ante partum prophylactic anti-D.	cost benefit study on the use?	
JDC	11/93	4.7.2	advise the Donor Consultants group that anti-zoster would be handled by the hyperimmune plasma procurement group.	Complete	
JG	11/93	4.7.2	produce an update report for the MSC on the activities of the hyperimmune plasma procurement group.	Outs discussion (appendix 2,	list this agenda)
RJP	11/93	4.7.3	Advise the Board as to how the SNBTS surplus of anti-D might be disposed of.		
CVP/ RJP	11/93	4.7.5	Advise Directors when firm information is available on the introduction of HPIX.		
RJP	11/93	4.7.6	Clarify normal human Ig supply and demand position before pursuing supply to GPs.		
RJP	11/93	4.7.7i	Produce a discussion paper for the Board on the long term SNBTS supply strategy for rabies Ig.		
JDC	11/93	4.7.7ii	Advise AK that the MSC consider rabies Ig stock should be held at RTCs.	Done	
JDC	11/93	4.8.1	Communicate SNBTS concern at the introduction of code 128.	Complete	
CVP	11/93	4.9	Prepare and distribute an appropriate briefing note re the Product Services Manager.		
RM/ DBLMcC	11/93	5.1.3	establish whether customers in W & SE wish to receive SDPs routinely for autologous bone marrow patients.		
JDC	11/93	5.1.4	report on progress re HLA typed platelet panel.		
JDC	11/93	5.3	revise the definitions of Transfusion Medicine/Hospital Blood Banking for discussion at the consultants meeting.	Complete	
JDC	11/93	5.4	advise Dr Goldberg that SNBTS data could be used.	Complete	
RJP/JDC	11/93	6.2	RJP to advise JDC of his views re adopting the Red Guide as the base SNBTS quality specification. JDC to advise DMCI of outcome.	Done, 29 Nov 1993	
ALL	11/93	6.3	Make nominations for SNBTS representatives to the UK Barcode Working Party		